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Abbreviations used
CMV: Cucumber mosaic virus
CMVTT: Cucumber mosaic virus containing the tetanus toxoid uni-
versal T-cell epitope tt830-843
eIL-5: Equine IL-5
HRP: Horseradish peroxidase
IBH: Insect-bite hypersensitivity
ISI: Insect-bite hypersensitivity severity index
MALDI: Matrix-assisted laser desorption ionization
MS/MS: Tandem mass spectrometry
PBST: PBS-Tween 0.1% (vol/vol)
VLP: Virus-like particle
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FETTELSCHOSS-GABRIEL ET AL 1195Objective: To target these cells and treat disease, we developed a
therapeutic vaccine against equine IL-5 (eIL-5), the master
regulator of eosinophils.
Methods: The vaccine consisted of eIL-5 covalently linked to a
virus-like particle derived from cucumber mosaic virus
containing the tetanus toxoid universal T-cell epitope tt830-843
(CMVTT). Thirty-four Icelandic horses were recruited and
immunized with 400 mg of eIL-5–CMVTT formulated in PBS
without adjuvant (19 horses) or PBS alone (15 horses).
Results: The vaccine was well tolerated and did not reveal any
safety concerns but was able to induce anti–eIL-5 autoantibody
titers in 17 of 19 horses. This resulted in a statistically significant
reduction in clinical lesion scores when compared with previous
season levels, as well as levels in placebo-treated horses.
Protection required a minimal threshold of anti–eIL-5
antibodies. Clinical improvement by disease scoring showed
that 47% and 21% of vaccinated horses reached 50% and 75%
improvement, respectively. In the placebo group no horse
reached 75% improvement, and only 13% reached 50%
improvement.
Conclusion: Our therapeutic vaccine inducing autoantibodies
against self IL-5 brings biologics to horses, is the first successful
immunotherapeutic approach targeting a chronic disease in
horses, and might facilitate development of a similar vaccine
against IL-5 in human subjects. (J Allergy Clin Immunol
2018;142:1194-205.)
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Insect-bite hypersensitivity (IBH) of horses, also known as
sweet itch, summer eczema, kasen, or Queensland itch, manifests
as chronic relapsing seasonal allergic dermatitis caused by the
biting of insects of the genus Culicoides.1-5
Culicoides species midges are found in various areas of the
world.6-8 The incidence of IBH correlates strongly with the
geographic distribution of Culicoides species, showing the high-
est incidence in some parts of Australia (60%).9-11 Overall,
approximately 10% of all horses worldwide are affected by
IBH,12-15 and in principle, all breeds can succumb to the allergic
disease. During warmer months of the year, IBH-affected horses
experience hairless, weeping, and sometimes even ulcerative le-
sions caused by inflammation and severe itching. Lesions are
characterized by hyperkeratosis, lichenification of the skin,
bleeding, swelling, scales, and crust formation. Histologic hall-
marks of IBH lesions are thickening of the stratum corneum,
epidermis, and dermis, with abundant fibrosis in the latter.9
Commonly, secondary infections with bacteria, mites, and fungi
can cause further local irritation, enhancing lesion formation.
Although IBH was first described in 1840 and is currently the
best characterized allergic disease in horses, treatment options
are still poor, and currently, no satisfactory treatment of IBH is
available.9,16
IBH is classified as IgE-dependent type I allergy,17 with a
strong involvement of type IV allergic hypersensitivity reac-
tions.4,18 In addition to IgE-mediated cross-linking of FcεRI
on mast cells and basophils with subsequent histamine release,
type I allergies also consist of a late-phase reaction with eosin-
ophilia and recruitment of eosinophils into the allergic site. In-
tradermal injection of Culicoides species extract into
IBH-affected horses leads to recruitment of TH2 cells andeosinophils to the injection site.19 Moreover, in addition to
the role of IgE and type I allergy in the setting of IBH, an
involvement of cell-mediated type IV allergic reactions, also
called delayed-type hypersensitivity, has been discussed in
recent years.16
Type IV allergies can be divided into 4 subgroups: (ie, types
IVa, IVb, IVc, and IVd) depending on the cell types involved.
Type IVb allergy is strongly associated with IL-5–producing TH2
cells, eosinophilia, and eosinophilic type of inflammation20 and
reflects the clinical manifestations of skin inflammation in IBH,
which are characterized by edema and eosinophil accumulation
in perivascular clusters in deeper parts of the dermis.21 These
enhanced eosinophils counts represent the predominant inflam-
matory cell type accumulating in IBH lesions.21,22 Activated eo-
sinophils release granule enzymes and other effector molecules,
such as histamine, eosinophil-derived neurotoxin, cysteinyl leu-
kotrienes, and major basic protein. Major basic protein triggers
degranulation of mast cells and basophils, thereby further
enhancing allergic symptoms.23 Cysteinyl leukotrienes derived
from arachidonic acid are inflammatory mediators contributing
on multiple levels to an allergic reaction, thereby making an
eosinophil a very effective cell type to cause strong allergic symp-
toms during late-phase and delayed-type reactions. Therefore
eosinophil degranulation can mediate hyperreactivity, inflamma-
tion, and local tissue damage, thus potentially driving the pathol-
ogy of IBH.24
To dampen eosinophil activity, we decided to target the
lineage-specific eosinophil master regulator IL-5, which is a
TH2-type cytokine producedmainly by TH2 cells and also bymast
cells. Eosinophil development in the bone marrow is critically
dependent on IL-5.25,26 Moreover, eosinophil release into blood
circulation is mediated by IL-5, and the cytokine plays a key
role in eosinophil activation.27 Also, IL-5 increases survival of
tissue-resident inflammatory eosinophils.28 Mice either vacci-
nated against murine IL-5 or IL-5–deficient knockout mice
show strongly reduced levels of blood eosinophils and
eosinophil-mediated inflammation.26,29 Furthermore, mepolizu-
mab, a humanized anti–IL-5 mAb, significantly reduced circu-
lating eosinophil counts in human subjects and has shown
clinical efficacy in patients with eosinophil-mediated diseases,
such as eosinophil-mediated asthma and hypereosinophilic syn-
drome.30-34 Thus blocking IL-5 can lead to effective control of
IBH.
Instead of targeting IL-5 with mAbs,35 which is not a realistic
approach because of the weight of a horse, we developed a
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1196 FETTELSCHOSS-GABRIEL ET ALvirus-like particle (VLP)–based therapeutic vaccine that induces
IL-5 autoantibodies in the host. VLPs are supramolecular
structures composed of multiple copies of 1 (or more) recombi-
nantly expressed structural viral proteins, which spontaneously
assemble into capsid particles but lack genetic information and
therefore do not have replicative capacity, which is an important
safety aspect. The highly repetitive surface, particulate structure,
and induction of innate immunity through pathogen-associated
molecular patterns is responsible for induction of fulminant B-
and T-cell responses.36,37 VLPs can be derived from a large
number of viruses, including bacteriophages and plant
viruses,38,39 and are used for the development of a wide range
of different prophylactic and therapeutic vaccines.
Here we used a recently developed and novel VLP platform
based on the cucumber mosaic virus containing the tetanus
toxoid universal T-cell epitope tt830-843 (CMVTT) to enhance
TH cell–dependent IgG responses for antigens displayed on
the VLP surface.40 We show that a vaccine consisting of equine
IL-5 (eIL-5) chemically linked to CMVTT-VLPs induces potent
anti–eIL-5 antibody responses, which improve symptoms of
IBH in horses.METHODS
Horses and clinical study
All study horses were Icelandic horses and privately held by their owners.
All clinical studies were approved by the respective cantonal veterinary
authorities. All horse owners signed informed consent. The clinical study was
performed as a double-blind, placebo-controlled randomized trial; neither the
person that performed the clinical trial nor the horse owners knew the group
identity of the horses. The independent vaccine filler has randomized the study
and was not involved in any clinical part of the study.IBH lesion scoring
For IBH symptom scoring, all locations (tail, mane, belly, flank, face, ear,
leg, and the like) at which IBH lesions occurred were recorded. Each location
was divided into 3 parts: up, middle, and down. Furthermore, according to the
number of lesions, each locationwas classified as light or strong, depending on
the frequency of lesions within the particular area. Depending on how many
parts are affected (up/middle/down) and how many lesions per location were
found (light/strong), 1 to 4 points were scored (1 point 5 one part affected,
lesion light; 4 points 5 all 3 parts affected, lesion strong). Moreover, these
locations were classified for 6 further properties: size (diameter), blood
(occurrence of bleeding), hair loss, scales, crust, and lichenification/swelling.
For all these properties, 1 to 4 points were also scored. Lesion sizewas divided
into 1 point (<0.5 cm), 2 points (0.5 <_3 < 1 cm), 3 points (1 <_3 < 2 cm), and 4
points (>_2 cm). The ‘‘blood’’ criteria served to distinguish between intact
epidermis (1 point) or whether mild (2 points), moderate (3 points), or severe
(4 points) bleeding occurred. Hair loss was divided into mild (1 point),
moderate (2 points), severe (3 points), and absence of hair (4 points). Scales
were divided into none (1 point), tiny and few (2 points), moderate and
midsized (3 points), andmany and big (4 points) scales. Crust was divided into
none (1 point), tiny (2 points), half (3 points), and total (4 points). Lichen-
ification and/or swelling were divided into none (1 point), mild (2 points),
moderate (3 points), and severe (4 points). Additionally, if the sheath or udder
was swollen, a minimum of 5 or a maximum of 20 points were scored: grade 1
(5 points), grade 2 (10 points), grade 3 (15 points), and grade 4 (20 points).
Finally, all points were summed to produce the IBH symptom (or lesion) score.
The D average lesion score was calculated for placebo-treated and
vaccinated horses as follows. Lesion scores for all horses were recorded
monthly during the observation period within each IBH season. For each
horse, the average lesion score was calculated per season. The D average
lesion scorewas defined by subtracting the pretreatment season average lesionscore by the treatment season average lesion score. The average of the
resulting differences was calculated and is reported here as D mean average
lesion score.Blood withdrawal
Blood was collected from the jugular vein at the intersection of the
proximal to median third of the neck.Blood analysis with IDEXX Diavet and production of
horse sera and plasma
For differential blood analysis and determination of IgE levels against
Culicoides species, blood was collected in tubes provided by IDEXX Diavet
(Freienbach, Switzerland). Differential blood analysis was done with fresh
EDTA blood. IgE levels against insects were determined in serum, EDTA
plasma, and Lithium Heparin plasma; tubes were centrifuged at 3000 rpm
for 10 minutes, and serum or plasma was transferred into fresh tubes.
IgE-specific Culicoides species ELISA was performed by IDEXX Diavet
with Culicoides species whole-body extract.Detection of recombinant eIL-5 by anti–IL-5 ELISA
Maxisorp 96-well ELISA plates (Nunc; Thermo Fisher) were coated
overnight with 50 mL of anti-His antibody at 0.5 mg/L. Plates were washed 3
times with PBS-Tween 0.1% (vol/vol; PBST) and then blocked with Super-
block (Thermo Scientific, Waltham, Mass) for 1 hour at 378C. Plates were
washed twice with PBST, and purified recombinant eIL-5–C-His was titrated
starting with addition of 10 mg/L diluted 1:3 and incubated for 1 hour. Blank
wells contain Superblock without recombinant protein. Then plates were
washed 3 times with PBST and 1 ng/mL anti–eIL-5 antibody (eIL-5 affinity
purified polyclonal antibody, catalog no. AF2470; R&D Systems, Abingdon,
United Kingdom) was added and incubated at room temperature for 2 hours.
Plates were washed subsequently 3 times with PBST and incubated with a
secondary anti-goat IgG conjugated with horseradish peroxidase (HRP;
dilution 1:2000) at room temperature for 30 minutes. Plates were again
washed 3 times with PBS, and 50 mL/well developing solution (TMB) was
added. After 2 minutes of reaction at room temperature, the ELISA was
stopped with 25 mL/well at 5% H2SO4. Absorbance was measured at 450 nm
on a Tecan M200 spectrophotometer (Tecan, Gr€odig, Austria).eIL-5 levels in horse serum
ELISA was conducted according to the manufacturer’s manual (R&D
Systems).Anti-CMVTT and anti–IL-5 antibody titer
determination
Maxisorp 96-well ELISA plates (Nunc) were coated overnight with
purified eIL-5–C-His or purified CMV (5 g/L). Plates were washed 3 times
with PBST and blocked with Superblock (Thermo Scientific) for 2 hours at
room temperature. Then plates were washed 3 times with PBST, and 3-fold
dilutions of 1:10 diluted horse sera (in Superblock) were added and
incubated at room temperature for 2 hours. Plates were washed subsequently
3 times with PBST and incubated with anti-equine IgG (1:2000) conjugated
with HRP (Jackson ImmunoResearch, West Grove, Pa) at room temperature
for 30 minutes. Plates were again washed 4 times with PBS, and developing
solution (TMB) was added. After approximately 2 minutes of reaction at
room temperature, the ELISAwas stopped with 5% H2SO4. Absorbance was
measured at 450 nm (OD450) on a Tecan M200 spectrophotometer (Tecan).
The antibody titer as OD50 was calculated (serum dilution on a logarithmic
scale where OD450 was half maximal). All antibody titers are calculated
with naive serum subtracted on logarithmic scales and presented as
DOD50 values. Titers of less than 10 (and including 10) were considered
as background.
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staining
Punch biopsy specimens (6 mm) from lesions of IBH-affected horses were
stained with hematoxylin and eosin and CD3 (Vetsuisse Faculty, Zurich,
Switzerland).Cloning, expression, and purification of
recombinant eIL-5
The DNA sequence encoding mature eIL-5 (Equus caballus; UniProt
O02699) was generated by means of gene synthesis. In addition, a
3-amino-acid linker (GGC) was added C-terminally. This insert was flanked
by 59 NdeI and 39 XhoI and integrated into pET 42b (1), containing a hexa
His-tag (to facilitate purification) and an in-frame stop codon. The resulting
eIL-5 fusion protein was expressed in Escherichia coli BL21 (DE3) cells.
Overnight cultures were grown and diluted in LB medium containing
50 mg/L kanamycin. Isopropyl-b-D-thiogalactopyranosid was added to a
final concentration of 1 mmol/L when an OD600 of culture reached 0.7.
The culture was harvested by means of centrifugation 4 hours after induc-
tion, and the pellet was resuspended in 100 mmol/L Tris/HCl (pH 8.0) at
48C and 1 mmol/L EDTA. Inclusion bodies were prepared, and insoluble
eIL-5 was solubilized in denaturing buffer (6 mol/L GdmCl, 20 mmol/L
imidazole, and 100 mmol/L Tris-HCl [pH 8]). After centrifugation for
20 minutes at 20,000g, the supernatant containing denatured, soluble,
recombinant eIL-5 was purified through the His-tag by using Ni-NTA
(Ni-NTA Sepharose 6 Fast Flow, Amersham, Piscataway, NJ, or NiNTA
Superflow, Qiagen, Hilden, Germany) column and eluted by using
6 mol/L GdmCl, 100 mmol/L NaH2PO4, and 10 mmol/L Tris-HCl
(pH 4.5) with subsequent dialysis to pH 8.0. Accordingly, eIL-5 was
refolded by means of sequential dialysis against the following buffers at
pH 8.5 at 48C: buffer 1 (2 mol/L urea, 50 mmol/L NaH2PO4, 5 mmol/L
reduced glutathione, 0.5 mmol/L oxidized glutathione, 0.5 mol/L arginine,
and 10% glycerol), buffer 2 (50 mmol/L NaH2PO4, 5 mmol/L reduced
glutathione, 0.5 mmol/L oxidized glutathione, 0.5 mol/L arginine, and
10% glycerol), buffer 3 (50 mmol/L NaH2PO4 and 10% glycerol), and
buffer 4 (PBS). Finally, refolded protein was concentrated by using Amicon
Centrifugal Filters (Ultrafree-15 [Millipore, Temecula, Calif], 10 kDa
MWCO) and purified on a HiLoad 26/60 Superdex 75 prep grade
(GE Healthcare, Fairfield, Conn) with PBS buffer. Protein concentrations
were determined by using the Bradford assay to BSA standard.Circular dichroism spectroscopy of purified
eIL-5–C-His
The far-UV circular dichroism spectrum of purified eIL-5–C-His (in PBS)
was measured on a J-710 spectropolarimeter (Jasco, Easton, Md) at 258C by
using a 1-mm cuvette. After correction for the buffer spectrum, ellipticity was
converted to mean residue ellipticity, as previously described.41Coupling of eIL-5 to CMVTT
VLP-CMVTT derived from CMVand containing the tetanus toxoid univer-
sal T-cell epitope tt830-843 was expressed in Escherichia coli by using the
expression plasmid pET28e, as previously described.40 The CMV concentra-
tion was determined by using the Bradford assay to a BSA standard. CMVwas
reacted with a 10-fold molar excess of the heterobifunctional cross-linker suc-
cinimidyl-6(b-maleimidopropionamido)hexanoate in 20 mmol/L NaP/
2 mmol/L EDTA, pH 7.5, at 258C (Pierce, Rockford, Ill). Unreacted cross-
linker was removed by means of passage over a PD-10 desalting column
(GE Healthcare). Recombinant, purified, and refolded eIL-5–C-His was
reduced for 1 hour with an equimolar amount of tri(2-carboxyethyl)phosphine
hydrochloride in PBS (pH 8.0) to reduce the cysteine residue contained in the
linker. The reduced eIL-5–C-His was thenmixedwith the derivatized CMVTT-
VLPs at a molar ratio of CMVTT monomer to eIL-5–C-His protein monomer
of 1:2 and coincubated for 4 hours at 228C in PBS (pH 7.4) to allow cross-
linking.SDS-PAGE and Coomassie staining
Separation of proteins with 4-12% Bis-Tris SDS-PAGE gels was done with
a prestained SeeBlue marker (Thermo Fisher) and MES buffer (NuPAGE;
Novex, Invitrogen Life Technologies, Grand Island, NY) at 200 V for
55 minutes. For coupling analysis, equimolar amounts of CMVTT, eIL-5–C-
His, and eIL-5–C-His–CMVTT VLPs were separated by using SDS-PAGE,
4-12% B/T gel (NuPAGE, Invitrogen), and MES buffer at 200 V for 55 mi-
nutes. Subsequently, the gel was stained with Coomassie Blue (0.025% Coo-
massie Brilliant Blue R-250, 40% methanol, and 10% acetic acid) and
destained with destainer (40% methanol and 10% acetic acid). The coupling
efficiency (ie, moles of CMV–IL-5/moles of CMVmonomer [total]) was esti-
mated by using densitometric analysis of the Coomassie Blue–stained SDS-
PAGE with ImageJ software (National Institutes of Health, Bethesda, Md).Western blotting
CMVTT, eIL-5–C-His, and IL-5–C-His–CMVTT vaccinewere separated by
using SDS-PAGE and electroblotted onto a nitrocellulose membrane. The
membrane was blocked for 1 hour with 5% (wt/vol) BSA powder in PBST
and then incubated with 10 mL of 1:1000 diluted anti-His antibody (Penta-
His Antibody, BSA-free, mouse monoclonal IgG1; Qiagen) in 1% BSA (wt/
vol) powder in PBST. The membrane was washed with PBST for 15 minutes
and then incubated for 1 hour with 10 mL of 1% (wt/vol) BSA in PBST con-
taining an anti-mouse IgG antibody conjugated with HRP at a dilution of
1:10,000. The membrane was washed for 15 minutes in PBS and developed
with ECL (Amersham Pharmacia, Sweden) and exposed to photographic film.Vaccine administration and immunization regimen
Horses (n 5 19) were injected subcutaneously on days 0, 28, 56, and 84
with 400 mg of eIL-5–C-His–CMVTT VLPs in 1000 mL of PBS without addi-
tional adjuvants to generate self-reactive antibodies to eIL-5. All horses
received a booster immunization on day 140. Placebo-treated horses
(n 5 15) received PBS instead at all respective time points.Parasite load
Fresh feces was collected from horses before and after vaccination and was
analyzed at IDEXX Diavet by using the combined sediment/float method,
distinguishing gastrointestinal nematodes, coccidian oocysts, and tapeworm
eggs/body parts. For each time point (before and after vaccination), a value of
1 was allocated to horses with helminths, and a value of 0 was allocated to
horses without helminths. Mean helminth values were calculated for eIL-5–
CMVTT–vaccinated and placebo-treated horses. The D helminth load for
placebo-treated or vaccinated horses was calculated by subtracting the mean
value after treatment from the mean value before treatment.Statistics
All graphs comparing vaccinated horses versus placebo-treated horses
show means and SEMs. For statistical analysis, vaccine horses versus placebo
horses were compared by using an unpaired 2-tailed Student t test. P values of
less than .05 were considered to be statistically significant.RESULTS
Eosinophil counts but not IgE levels correlate with
disease severity
To compare the influence of levels of Culicoides species–
specific IgE versus eosinophil counts, we clinically scored signs
of IBH (by score sheet, see Fig E1 in this article’s Online Repos-
itory at www.jacionline.org) in affected horses for a whole season
and analyzed blood for blood eosinophil counts and Culicoides
species–specific IgE levels using a commercial serologic test.
Blood was taken in the season before vaccination. Eleven of the
FIG 1. Diagnostics and characterization of IBH. A-D, Correlation of IBH lesion scores to blood parameters.
IBH lesion scores were determined in biweekly to 4-week intervals during a whole season (April until
October). Average lesion scores per horse were generated. EDTA blood and serum were taken once during
the season with high symptoms (August). Eosinophil levels (EDTA blood) and Culicoides species–specific
IgE levels (serum) were quantified by IDEXX Diavet. Correlation between average lesion scores and Culi-
coides species–specific IgE levels (IgE levels >150 ELISA absorbance units [EA] are considered allergic;
dotted gray line; Fig 1, A), blood eosinophil count (Fig 1, B), serum IL-5 levels (quantified bymeans of ELISA;
Fig 1, C), and blood eosinophil counts in a larger cohort (Fig 1, D) are shown. E and F, IBH skin biopsy.
A representative skin biopsy specimen of a fresh lesion from an IBH-affected horse. Fig 1, E, Eosinophils
in an IBH skin biopsy specimen. Hematoxylin and eosin staining was used. An overview (scale
bar 5 800 mm, upper panel) and enlarged section (scale bar 5 200 mm, lower panel) are shown.
Eosinophil-rich regions in the enlarged section are marked by circles. Fig 1, F, T cells in an IBH biopsy spec-
imen. CD3 stainingwas used. An overview (scale bar5 300 mm) is shown. A CD31-rich region ismarked by a
circle.
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IgE levels of greater than the cutoff of 150 ELISA absorbance
units. However, 1 horse with very severe clinical signs of IBH
(average IBH score, 99) had levels less than the cutoff, andoverall, IgE levels did not correlate with average scores of
seasonal IBH severity (Fig 1, A). In contrast, there was a strong
positive correlation between average seasonal IBH scores
and eosinophil count in blood at time points of active disease
FIG 2. Production and characterization of eIL-5 protein. A, SDS-PAGE analysis of purified eIL-5–C-His. Sam-
ples from various stages of the inclusion body preparation and purification were applied to a 4-12% B/T gel
and run under reducing conditions. Proteinswere stained with Coomassie Blue. LaneM, Sizemarker; lane 1,
lysate (sample A); lane 2, soluble fraction (sample B); lane 3, solubilized inclusion bodies (sample C); lane 4,
flow through (unboundmaterial, sample D); and lane 5, pooled eIL-5 monomer (eIL-5, m) eluate from the Ni-
NTA column (sample E). B, SDS-PAGE of refolded recombinant eIL-5–C-His. An aliquot of purified eIL-5–C-
His was separated on a 4-12% B/T gel and run under nonreducing conditions (1SDS, no dithiothreitol, no
heating). Proteins were stained with Coomassie Blue. eIL-5, d, eIL-5 dimer; eIL-5, m, eIL-5 monomer.
Lane M, Size marker; lane 1, pooled denatured eluate from the Ni-NTA column; lane 2, refolded and homo-
dimer enriched eIL-5–C-His. C, Far-UV circular dichroism spectrum of purified eIL-5–C-His. The spectrum
demonstrates that eIL-5–C-His was folded. D, Detection of purified eIL-5–C-His with commercial anti–eIL-5
antibody. Anti-His antibody–coated ELISA plates were incubated with purified eIL-5–C-His and detected
with a commercially available anti–eIL-5 antibody.
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correlated to average seasonal IBH scores, thereby indicating a
link between levels of eIL-5 and IBH-associated eosinophilia
(Fig 1, C). The correlation of eosinophil blood counts with IBH
scores was also seen when a second larger cohort of horses was
assessed (Fig 1, D). A representative biopsy of a skin lesion
stained with hematoxylin and eosin is shown in Fig 1, E,
confirming recruitment of blood eosinophils to the skin. In
addition to the remarkable eosinophil infiltrates, the most
abundant other cell type also associated with skin pathology
was the CD31 T cell (Fig 1, F). Furthermore, the typical
hyperkeratosis accompanied by acanthosis can be found,
fulfilling the histologic hallmarks of an IBH lesion (Fig 1, E).
Taken together, blood eosinophil counts correlate strongly with
IBH severity scores and therefore might not only be useful to
monitor IBH severity but also are an attractive target in IBHtherapy. Consequently, a therapy treating eosinophilia is likely to
influence the magnitude of disease severity.Production of therapeutic vaccine
To induce autoantibodies against eIL-5, we coupled eIL-5 to
VLPs, creating a hapten-carrier complex and thus bypassing
B-cell unresponsiveness against self IL-5 by introducing
VLP-specific intermolecular T-cell help.42
Recombinant eIL-5 with a C-terminal linker containing a free
cysteine residue and a His-tag (eIL-5–C-His) was produced
in E coli and purified by means of affinity chromatography
(Fig 2, A), refolded, and polished by using size-exclusion
chromatography. Because biologically active native IL-5 is a
disulfide-linked homodimer, the ability of purified recombinant
eIL-5–C-His to form dimers after refolding was assessed by using
FIG 3. Vaccine production and analysis of the coupling reaction of eIL-5–C-His to CMVTT. A and B: Lane M,
Size marker; lane 1, tri(2-carboxyethyl)phosphine hydrochloride (TCEP)–activated eIL-5–C-His; lane 2, CMV-
VLP after derivatization with the chemical cross-linker succinimidyl-6(b-maleimidopropionamido)hexa-
noate (SMPH); lane 3, eIL-5–C-His–CMVTT coupling reaction. eIL-5–C-His, CMVTT, and eIL-5–CMVTT were
loaded in an equimolar manner to compare coupling efficacy. A, SDS-PAGE. Proteins were stained with
Coomassie Blue. c, Coupling; CMV, m, CMVTT monomer; eIL-5, d, eIL-5 dimer; eIL-5, m, eIL-5 monomer.
B,Western blotting with a-His antibody staining. c, Coupling; eIL-5, d, eIL-5 dimer; eIL-5, m, eIL-5 monomer.
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lane 2). As judged by the molecular mass of approximately
28 kDa, eIL5–C-His was indeed dimeric in nature, indicating con-
servation of the native tertiary structure. Far-UV circular dichro-
ism spectroscopy confirmed that purified eIL-5–C-His was folded
and, as expected and indicated by the minima at 208 and 222 nm,
adopted a mostly a-helical secondary structure (Fig 2, C).
Furthermore, a commercially available anti–eIL-5 mAb also
recognized the refolded dimeric eIL-5 (Fig 2, D). In the native
structure of the IL-5 dimer, the 2 monomers are linked by 2 inter-
molecular disulfide bridges (between Cys44 of one monomer and
Cys86 of the other and vice versa), leading to a head-to-tail posi-
tioning of the 2 monomers with respect to each other.43 In partic-
ular, linkage of 2 monomers by 2 intermolecular disulfide bridges
was analyzed by using liquid chromatography–matrix-assisted
laser desorption ionization (MALDI)–tandem mass spectrometry
(MS/MS) after trypsin digestion of eIL-5–C-His. MS/MS frac-
tions of mass 2505, 2633, and 2761 m/z showed the typical disul-
fide fragment pattern 32/2/32, confirming intermolecular linkage
of 2 IL-5 monomers through Cys44 to Cys86 (see Fig E2 in this
article’s Online Repository at www.jacionline.org).
The eIL-5–C-His homodimers were chemically coupled to
VLPs derived from the cucumber mosaic virus (CMVTT) through
the heterobifunctional cross-linker succinimidyl-6(b-maleimido-
propionamido)hexanoate to produce aVLP-based vaccine against
IL-5. Derivatization of VLPs shows the typical VLP ladder with
CMV monomeric and multimeric subunits (Fig 3, A, lane 2).29
Coupling of CMV subunits with dimeric eIL-5–C-His molecules
(Fig 3, A, lane 1) is shown on a reducing SDS-PAGE gel byadditional coupling bands that correspond to the molecular
mass of monomeric or dimeric eIL-5 plus monomeric or multi-
meric CMV subunits (Fig 3, A, lane 3). Successful covalent
attachment of eIL-5–C-His to CMVTT was confirmed by using
Coomassie staining (Fig 3, A) and Western blotting with an
anti-His antibody (Fig 3, B). Coupling efficiency for all batches
was between 20% and 50%.Antibody titer responses on vaccination
Horses were immunized with 400 mg of eIL-5–CMVTT formu-
lated in PBS on days 0, 28, 56, 84, and 140. Placebo-treated horses
received PBS. The reasons to use PBS and not CMVTTwithout IL-
5 coupled to a placebo were 2-fold: (1) placebo in registration
studies will be PBS and not CMVTT without IL-5 coupled to it,
and (2) we planned to immunize the placebo-treated horses in
the following season, which would have been impossible if they
had been immunized with CMVTT alone because of carrier-
induced epitope suppression.44 Therefore we decided to use
PBS as a control. Antibody titers in horse serum were evaluated
monthly after vaccination and were consistently detectable after
the second injection (Fig 4). The third and fourth injections main-
tained antibody responses against eIL-5 (Fig 4, A) and CMVTT
(Fig 4, B). Variation between single horses was less pronounced
for anti-CMVTT VLP antibody titers (Fig 4, D) than for antibody
titers against the self-molecule eIL-5 (Fig 4, C). However, and in
contrast to anti-CMVantibodies, anti–IL-5 antibodies can bind to
their target antigen, IL-5, in serum. Hence such antigen-antibody
complexes might not be detectable by using classical ELISA.
FIG 4. Antibody titer of vaccinated horses against eIL-5 and CMVTT-VLP. Time points of vaccinations are
indicated by gray arrows. A, Mean antibody titer of anti–eIL-5 IgG. B, Mean antibody titer of anti-CMV
IgG. C, Antibody titer of anti–eIL-5 IgG of individual horses. D, Antibody titer of anti-CMV IgG of individual
horses.
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son for both eIL-5 and CMV (Fig 4).Reduced IBH lesion scores in
eIL-5–CMVTT–vaccinated horses
Lesion scores of study horses were recorded monthly in the
pretreatment season and the subsequent treatment year from
March until October. Data were analyzed according to an
intention-to-treat analysis, thus including all horses without
exclusions. Seasonal progression of average lesion scores of
placebo-treated horses were comparable for both seasons (Fig 5,
A), whereas average lesion scores of eIL-5–CMVTT–vaccinated
horses showed strongly improved clinical signs in the treatment
year when compared with those in the pretreatment season
(Fig 5, B). When comparing average lesion scores between both
seasons for all horses individually, the majority of vaccinated
horses showed pronounced lesion reduction in the treatment
year. In contrast, most placebo-treated horses did not improve
their symptoms (Fig 5, C). Analogous to Psoriasis Area and
Severity Index 50 and Psoriasis Area and Severity Index 75
scores, we defined the insect-bite hypersensitivity severity index
(ISI) 50 and ISI 75 (IBH severity index). ISI 50 represents a 50%
and greater reduction of symptoms, and ISI 75 represents a 75%
and greater reduction of symptoms. In total, 47% of vaccinated
horses reached an ISI 50, whereas in the placebo group only
13% reached this level of reduction. An ISI 75 was achieved in21% of the vaccinated horses, whereas none of the placebo-
treated horses showed such a pronounced improvement
(Fig 5, D). The D average lesion scores of eIL-5–CMVTT–
vaccinated horses showed a mean reduction in lesion scores of
28.5 6 4.5 (n 5 19), whereas the D average lesion score in
placebo-treated horses showed a mean reduction in lesion score
of 11.16 3.7 (n5 15). The difference between vaccinated horses
and placebo-treated horses was statistically significant, showing a
higher improvement in lesion symptoms in eIL-5–CMVTT–
vaccinated horses (P 5 .0073; Fig 5, E). Furthermore,
anti–eIL-5 serum antibody levels during the IBH season were
most likely required to be greater than a certain threshold to be
protective rather than showing a linear dependency (Fig 5, F).
For further IBH vaccine development, the observed antibody
threshold level can be used as a surrogate for clinical efficacy.Blood eosinophilia
Eosinophil counts for all horses were measured monthly after
vaccination or placebo treatment. During the IBH season, blood
eosinophil counts of placebo-treated horses peaked in June,
whereas lesion scores peaked with a delay of approximately
1 month in July. Mean blood eosinophil counts in placebo-treated
horses had been found above maximal standard values from May
until October, with a slight decrease in peak levels in July and
October (Fig 6, A). In general, blood eosinophil counts of
placebo-treated horses correlated well with lesion scores of the
skin (Fig 6, B).
FIG 5. Lesion scores of eIL-5–CMVTT–vaccinated horses improved significantly compared with placebo-
treated horses in clinical study. A and B, Mean lesion score of placebo-treated horses (n 5 15; Fig 5, A)
and eIL-5–CMVTT–vaccinated horses (n 5 19; Fig 5, B) followed from March until October in the pre-
evaluation year (gray symbols) and treatment year (black symbols). Months with more than 1measurement
show average values. C, Average lesion score per horse of the previous season (Pre) versus the treatment
season (Treat; black: active, eIL-5–CMVTT vaccinated, n5 19; gray: placebo, n5 15). D, Percentage of horses
with 50% (black columns) and 75% (gray columns) lesion score improvement in eIL-5–CMVTT–vaccinated (V)
and placebo (P) group. E, DMean average lesion score from eIL-5–CMVTT–vaccinated horses (black column,
n 5 19) versus placebo-treated horses (gray column, n 5 15). **P < .01. F, Area under the curve (AUC) anti–
eIL-5 antibody (Ab) titer versus D average lesion score of placebo-treated horses (gray symbols, n5 15) and
eIL-5–CMVTT–vaccinated horses (black symbols, n 5 19). AUC includes all values during the whole treat-
ment season. All graphs include all horses (n 5 34) analyzed according to intention to treat.
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eosinophil counts, and there was a much less obvious correlation
between blood eosinophil count and lesion scores, indicating that
anti–IL-5 antibodies alter eosinophil inflammation in lesions but
had little influence on blood eosinophil counts (Fig 6, C).No increase in parasitic load after eIL-5–CMVTT
vaccination
The parasitic load of horses was quantified in excrement at
the start and end of the treatment year. No difference between
placebo-treated and vaccinated animals was observed when
comparing mean helminth load before and after treatment (Fig 7,
A) and change in mean helminth load (Fig 7, B). In
general, helminth burden in autumn was greater in both the
placebo-treated and vaccinated groups, probably because of higher
exposure to parasites on grazing land in the summer months.DISCUSSION
IBH is a frequent and sometimes devastating disease in horses.
Here we demonstrate that targeting eosinophils, the majorinflammatory cells in IBH lesions, with active vaccination against
the TH2 cytokine IL-5 strongly improves disease symptoms in
affected horses. This is a novel and allergen-independent
approach to manage IBH in horses that differs from the strategy
of Jonsdottir et al,45 who propose desensitizing horses through in-
tralymphatic injection of small doses of allergens in adjuvants.
Despite a missing correlation between allergen-specific IgE
levels and IBH severity, we showed that the severity of IBH
disease correlated well with blood eosinophil counts. Especially
in the setting of progressed IBH, eosinophils seemed to dominate
the allergic reaction. The eosinophilia is caused by a late phase of
type I and delayed-type allergic responses (type IV) to insect
bites. This is in contrast to insect venom allergy in human
subjects, in which eosinophilia has not been described. Thus
eosinophil-dependent IBH shares common aspects with human
asthma, which also has an IgE component but is eosinophil
driven.46 This implies that human allergy in the lungs seems to
share common aspects with equine allergy in the skin. However,
atopic dermatitis of human skin is a multifactorial and complex
disease with various trigger factors, only one of them being aller-
gens. Although serum concentration of human eosinophilic
cationic protein is a diagnostic marker for atopic dermatitis in
FIG 6. Interrelation between blood eosinophil counts and lesion scores. A, Mean blood eosinophil counts
(gray symbols and line, left y-axis) and mean lesion scores (black symbol and line, right y-axis) of placebo-
treated horses (n 5 15) determined in the treatment season from January until October or March until
October, respectively. The normal maximum blood eosinophil count is indicated by a dotted gray line.
Months with more than 1 measurement show average lesion score values. B, Eosinophil counts versus
lesion scores of all 15 placebo-treated horses for 10 time points from each horse. C, Eosinophil counts
versus lesion scores of all 19 vaccinated horses for 10 time points from each horse.
FIG 7. Side effect: parasitic load. A, Mean helminth burden in placebo-
treated horses (gray columns, n 5 15) and eIL-5–CMVTT–vaccinated horses
(black columns, n 5 19). No measureable helminths in excrement 5 0, de-
tected helminthes in excrement 5 1. Excrement was taken in the treatment
season before injections (pre) and at the study’s end in autumn (post). B,
Average seasonal change in helminth burden for placebo-treated (gray col-
umn) and vaccinated horses (black column) was calculated by subtracting
the mean value determined at the beginning from that at the end of the
treatment season.
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titis in human subjects.48 Thereforewe think that human asthma is
the correlate to equine IBH, although the affected organs differ.
IL-5 is a very well-validated target, and abundant data in mice
and human subjects indicate that blocking IL-5 is a safe and
efficacious way to reduce eosinophil-mediated inflammation.
Therefore IL-5 might be an ideal target for safe IBH therapy in
horses. Two different anti-human IL-5 antibodies have been
developed for the treatment of eosinophil-associated diseases,
such as hypereosinophilic syndrome or eosinophilic asthma:
mepolizumab (GlaxoSmithKline, Research Triangle Park, NC)
and reslizumab (Teva Pharmaceuticals, Petah Tikva, Israel). The
mechanism of action for an anti–IL-5 antibody is blockage of
eosinophil development, survival, and activation. Evidence fromeosinophil-deficient mouse models and mAb studies in human
subjects suggests that eosinophil depletion has a negligible effect
on immunity to infection and other essential host functions.26,28,49
Moreover, IL-5 is classified as a lineage-specific cytokine for eo-
sinophils only and has a central role in the differentiation, activa-
tion, and survival of eosinophils exclusively. Hence depletion of
this cytokine is expected to have limited negative effects on other
lineages than eosinophils. Therefore a treatment that specifically
targets eosinophils seems to have limited effects on the host.
Indeed, no safety issues were reported in any of the human trials
or after-market authorization.49,50 In linewith these findings, eIL-
5–CMVTT vaccinewas well tolerated in horses and did not predis-
pose to increased infections. Specifically, and given the fact that
eosinophils are known to have antiparasitic effects and horses
are natural hosts of certain intestinal helminths, no difference in
helminth burden was found during the study period when
comparing vaccinated and placebo-treated horses. However,
more detailed safety studies will be required because of limita-
tions of our placebo-controlled randomized clinical study,
including the number of horses and the facts that we only included
Icelandic horses and do not know yet the effect on helminth
burden during long-term treatment.
Two injections of eIL-5–CMVTT formulated in PBS induced
high levels of anti-self antibodies recognizing eIL-5. Vaccine
booster immunizations maintained these levels, whereas anti-
body responses decreased in the absence of further injections.
Hence vaccination against IL-5 induced high levels of antibodies
that were reversible in the absence of booster injections. High
antibody titers were also measured against CMVTT-VLPs and
were used as a surrogate marker of vaccination because the im-
mune system readily induces antibodies against the foreign
CMV particle. Responses against IL-5 were slightly more vari-
able than responses against the carrier VLPs, but responses
against IL-5 and the CMV carrier correlated well overall. This
is consistent with observations in human subjects immunized
against IL-1b and might indicate that the tightly packed VLP
surface is able to activate the immune system more consistently
than the IL-5 covalently attached to VLPs.51 Furthermore, and in
contrast to anti-CMV antibodies, anti–IL-5 antibodies can bind
to host IL-5 in the serum, and thus antibodies involved in
J ALLERGY CLIN IMMUNOL
OCTOBER 2018
1204 FETTELSCHOSS-GABRIEL ET ALantigen-antibody complexes might no longer be detectable in the
ELISA performed in this study. Natural variations in IL-5 levels
between subjects will perhaps lead to different rates of depletion
of anti–IL-5 antibodies and hence provide a perception of vari-
ability in anti–IL-5 antibody responses compared with CMV.
Similarly, as seen with anti–IL-5 mAbs in human subjects, we
showed that vaccine-induced anti–IL-5 autoantibodies in horses
were able to treat eosinophil-mediated symptoms. Clinical scores
improved in eIL-5–CMVTT–vaccinated horses when compared
with the previous season of the same horses and placebo-treated
horses of the same season. One major advantage of vaccines
over mAbs is that there is no induction of antitherapeutic anti-
bodies by the host because these polyclonal vaccine-induced an-
tibodies are self-made. This ensures that the therapeutic
vaccination can be given each year before the IBH season starts,
leading to high antibody titers during the disease period and
decreasing antibody titers during the unaffected time of year.
For human subjects, antibodies induced against mAbs are a
tangible problem that can limit the choice of therapeutics, an issue
commonly seen in certain mAbs (eg, infliximab).52,53 Along these
lines, to date, it is unclear how inbred the different horses are with
respect to antibody allotypes. Therefore immunogenicity of the
different horse breeds will be difficult to predict.
Another advantage of the vaccine’s approach is the low cost of
goods because much lower amounts of protein are needed for
immunization compared with mAbs, which are usually applied
based on body weight. Replacing the costly monoclonal therapies
with active vaccination might also be an attractive treatment
modality in human subjects, providing relief to health insurance
systems. Therefore it would be interesting and also worthwhile to
compare an anti-human IL-5 mAb versus human IL-5–VLP
vaccines in human subjects.
Blood eosinophil levels during an IBH season increased
typically in the spring and reached a peak in June. IBH lesion
development followed eosinophil counts, with some delay.
Overall, eosinophil counts in the blood of placebo-treated and
unmanipulated horses correlated well with skin lesion scores,
suggesting that in an unbiased system eosinophil levels in blood
are a good indicator of eosinophil counts in skin and lesion
severity. However, this correlation was lost in horses vaccinated
against eIL-5, most likely because eosinophils do not efficiently
enter tissues in the absence of IL-5. Of note, in the follow-up year
of this study, during which slightly greater anti–IL-5 responses
were induced, a statistically significant reduction of eosinophils in
blood was observed (unpublished data). An alternative explana-
tion for the absence of a correlation between blood eosinophil
counts and antibody titers in the present study might be that the
vaccine in the current vaccine preparation contained free non-
coupled IL-5, whereas in the follow-up study this free IL-5 has
been removed.
Taken together, eIL-5–CMVTT successfully induced autoanti-
bodies and mediated a statistically significant reduction in lesion
scores in vaccinated horses when compared with placebo-treated
horses and the pretreatment season. This is the first time that an
anticytokine vaccine has shown clinical efficacy for the treatment
of a disease in the target species and might facilitate the develop-
ment of a similar vaccine targeting IL-5 in human subjects.
We thank all the horse owners who participated with their horses in our
clinical studies. We thank Michael Fontaine and Hans-Uwe Simon for helpful
discussion.Clinical implications: Long-term treatment of horses affected
by recurrent insect-bite hypersensitivity might be possible by
using a vaccine targeting IL-5 and thus limiting eosinophil
development and recruitment to the affected organ skin.REFERENCES
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MALDI-MS/MS and HPLC of digested eIL-5–C-His
MALDI-MS/MS and HPLC of digested eIL-5–C-His were performed by
the Functional Genomic Center, Zurich. eIL-5 was freshly digested with 1 mg
of trypsin (20:1) in 0.1% TFA/PBS buffer, pH 5 to 6, and analyzed by using 2different HPLC columns (C8 and C18). Samples were mixed 1:1 with
matrix solution (1.4 mg/mL alpha-4-hydroxycinamic acid in 85% cerium
nitrate, 0.1% trifluoroacetic acid, and 1 mmol/L MALDI-MS/MS and HPLC
of digested eIL-5–C-His NH4H2PO4) and spotted on the target. MALDI-MS/
MS measurements were performed manually.
FIG E1. Score sheet lesion scoring. Results are as described in the Methods section of the main article.
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FIG E2. Liquid chromatography–MALDI-MS/MS of purified and trypsin-digested eIL-5–C-His. Dimers were
linked intermolecularly through 2 disulfide bridges through Cys44 of one monomer and Cys86 of the other
and vice versa.
J ALLERGY CLIN IMMUNOL
OCTOBER 2018
1205.e3 FETTELSCHOSS-GABRIEL ET AL
